Projekt · Dnr 2018-03052 · Källa: Vinnova

E!12402, VASIP, Vaccine Against Streptococcus suis Infections in Pigs, Intervacc AB

Koordinator
Intervacc AB
Projekttid
2018-11-01 till 2023-02-28 (avslutat)
Beviljat bidrag
5 000 000 SEK
Diarienummer
2018-03052

Beskrivning

Streptococcus suis is an important endemic pathogen of piglets, causing meningitis, arthritis, endocarditis and septicaemia with mortality rates of between 1% and 20%. Piglets are most susceptible to infection in the period immediately post-weaning leading to treatment with antibiotics and significant economic losses to the pig industry worldwide. This project aimed to develop and test the safety, immunogenicity and efficacy of a new recombinant fusion protein vaccine using a new experimental S. suis challenge system in recently-weaned piglets. Five recombinant fusion proteins comprised of a total of 22 proteins from Streptococcus suis were produced and formulated into a prototype vaccine to target multiple virulence pathways and account for variation across the population of S. suis. Pregnant sows were vaccinated with three doses of the prototype vaccine, generating high levels of antibodies in their blood sera and colostrum. Piglets from vaccinated sows acquired similarly high antibody levels in their blood serum, and were protected significantly against challenge with S. suis at both 4 weeks and 7 weeks of age.

Öppna hos Vinnova

Hittar Vinnova inte sidan? Sök på diarienumret hos Vinnova.

Liknande

  1. E!4692, VASIP, Intervacc

    Intervacc AB · 2024-04-01 · 5 000 000 SEK · Projekt

    Streptococcus suis (S. suis) is an important endemic pathogen generating significant economic losses in the pig industry worldwide. Piglets develop disease post-weaning at between 4 and 10 weeks of age as the levels of maternal antibodies, which were passively acquired via the consumption of colostr…

  2. Nytt vaccin mot mastit hos nötkreatur orsakad av Staphylococcus aureus

    Intervacc AB · 2020-05-01 · 1 943 296 SEK · Projekt

    Mastitis is one of the most important diseases in dairy cattle causing significant losses to the dairy industry. Staphylococcus aureus is the causative agent of around 25% of contagious mastitis cases in Europe, accounting for over 2.6 million cases at an annual cost of 597M€. This project aimed to …

  3. Nytt effektivt Stafylokockus aureus vaccin mot Mastit som ersätter antibiotikaanvändning

    SAVACC AB · 2019-05-30 · 890 000 SEK · Projekt

    SLU är ett universitet och fordrar publisering. Ett Staphylococcus aureus (SA) vaccin har framställt som är innovativt både vad gäller antigen och adjuvans. Det har framkallat potenta antikrops nivåer me blod serum och mjölk. Vi tror SAvaccinet skall framakalla skudseffekt The test vaccine Chrivacc …

  4. E!11019, OptiFemVac, Abera Bioscience AB

    Abera Bioscience AB · 2017-04-01 · 2 351 980 SEK · Projekt

    The purpose was to engineer bacterial outer membrane vesicles (OMVs) into a versatile and modular platform for recombinant vaccine development. Technology was developped to couple high amounts of antigenic proteins to OMV particles and vaccine candidates against either Zika virus or Humano papiloma …

  5. Improved, affordable single strain whole cell-B subunit oral cholera vaccine

    Göteborgs universitet · 2017-06-01 · 5 950 000 SEK · Projekt

    The goal has been to develop an improved, thermostable and affordable enterocoated capsule oral cholera vaccine (OCV), "Hillchol-B", based on lyophilized formalin-inactivated serotype Hikojima bacteria and recombinantly produced cholera toxin B subunit (rCTB). This has been accomplished at lab scale…